Table 2.

Mean urinary (+SD) levels of 10 biomarkers assessed by ELISA in cohort of 320 subjects

	Total Bladder Cancer (57.2%) n = 183	Low-Grade Bladder Cancer (24.1%) n =77	High-Grade Bladder Cancer (30.6%) n = 98	NMIBC (87.4%) n =153	MIBC (12.6%) n = 22	Total Controls (42.8%) n = 137
IL8 (pg/ml) * ^ +	599±1765	269±1260	877±2095	461±1536	1644±2903	300±1355
MMP9 (ng/ml) ^ +	15.4±65.6	4.86±13.7	24.2±88.0	9.79±31.5	56.9±167	29.7±154
SERPINA1 (ng/ml) * ^ +	26.1±100	21.2±105	30.8±101	21.8±96.3	59.6±135	3.76±22.3
ANG (pg/ml) * ^	460±766	300±616	608±867	432±731	752±1037	293±633
VEGFA (pg/ml) * ^	623±669	532±681	710±670	583±606	969±1014	345±322
CA9 (pg/ml) * ^ +	103±562	51.5±171	150±752	91.5±583	212±513	7.02±42.6
MMP10 (pg/ml) * ^	21.6±187	36.2±286	11.6±34.8	25.0±204	4.53±13.6	6.96±46.3
APOE (pg/ml) *	0.011±0.049	0.005±0.017	0.013±0.057	0.007±0.020	0.029±0.11	0.003±0.007
SERPINE1 (ng/ml) * ^ +	3866±10518	1773±4223	5621±13626	3478±10589	7061±11365	2487±6713
SDC1 (pg/ml) * +	141±869	62.9±57.9	207±1185	143±948	146±171	37.0±54.0

NMIBC, non-muscle invasive bladder cancer MIBC, muscle invasive bladder cancer

^*, p < 0.05 comparing Total Bladder Cancer to Total Controls

^{^}, p < 0.05 comparing low-grade bladder cancer to high-grade bladder cancer

⁺, p < 0.05 comparing NMIBC to MIBC